Core Insights - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing medicines for serious diseases, including eye diseases, cancer, and allergic conditions, competing with major players like Amgen and Biogen [1] Group 1: Stock Performance - Cowen & Co. reiterated its "Buy" rating for Regeneron, with the stock priced at $764.11, suggesting confidence in the company's future performance [2] - The stock price has seen a slight increase, currently at $768.64, up by approximately 1.15% from the previous session, indicating positive market sentiment [4] - Regeneron's market capitalization stands at approximately $79.86 billion, reflecting its significant presence in the biotechnology industry [5] Group 2: Company Events - Regeneron participated in the TD Cowen 46th Annual Health Care Conference, showcasing its latest developments and strategies to key players and stakeholders [3] - The trading volume for the day is 132,758 shares, indicating active investor interest [5]

Core Viewpoint - Aditxt, Inc. has completed a 1-for-8 reverse stock split to support compliance with Nasdaq requirements, with trading of the adjusted shares beginning on March 9, 2026 [3]. Group 1: Reverse Stock Split Details - The reverse stock split was effective after market close on March 6, 2026, consolidating every 8 pre-split shares into 1 post-split share, with fractional shares rounded up [3]. - The split was approved by stockholders during a special meeting held on February 13, 2026, with the board determining the split ratio [3]. Group 2: Market Performance Post-Split - On the first day of adjusted trading, March 9, 2026, ADTX exhibited typical volatility for post-split micro-cap stocks, with prices fluctuating between $3.50 and $4.30, closing at approximately $3.83 [2]. - The pre-split price was around $0.47 as of March 6, indicating a significant increase in value post-split [2]. - The market capitalization remains low, approximately in the $2 million range, reflecting ongoing penny stock characteristics and compliance efforts [2].

Core Insights - ADMA Biologics is a significant player in the medical sector, focusing on specialty plasma-derived products [1] - Recent insider trading by director Steve Elms indicates confidence in the company's future [1][6] Financial Performance - ADMA Biologics showcases strong financial health with net margins of 28.8%, return on equity of 37.52%, and return on assets of 27.87%, highlighting profitability and resource efficiency [2] - The company maintains a low debt-to-equity ratio of 0.17, indicating a conservative approach to debt management [5] - A strong current ratio of 6.71 demonstrates robust liquidity, ensuring the company can meet short-term liabilities [5] Market Valuation - ADMA's market valuation is reflected in its price-to-earnings (P/E) ratio of 24.45, price-to-sales ratio of 7.05, and enterprise value to sales ratio of 7.03, indicating investor willingness to pay for its earnings and sales [4] - The enterprise value to operating cash flow ratio is high at 71.19, reflecting its valuation relative to cash flow [4] Ownership Structure - Institutional investors hold 75.7% of ADMA's shares, indicating strong confidence in the company's long-term growth potential [3] - Insider ownership is at 3.7%, which is lower than Rezolute's 14.8%, suggesting a more significant role of institutional investors in ADMA's ownership structure [3]

Core Viewpoint - 3D Systems Corporation reported Q4 2025 results with revenue exceeding estimates but continued challenges in profitability, as adjusted losses were wider than expected [1][3]. Financial Performance - Q4 2025 revenue was $106.3 million, surpassing consensus estimates of approximately $98 million, although it represented a year-over-year decline [3]. - Adjusted EPS was -$0.13, missing estimates of around -$0.10 [3]. Valuation Metrics - The price-to-sales ratio is approximately 0.7, indicating the market values the company below its annual sales [2]. - The enterprise value to sales ratio stands at about 0.64, reflecting the company's valuation relative to its sales [2]. - The company has a debt-to-equity ratio of approximately 0.87, indicating a moderate level of debt [2]. - A current ratio of about 2.73 demonstrates strong liquidity, allowing the company to effectively cover its short-term liabilities [2][3].

Core Viewpoint - Kohl's Corporation is facing challenges in a competitive retail environment, with anticipated declines in earnings and revenue for the upcoming quarter [2][3][6] Financial Performance - Analysts expect Kohl's to report earnings per share (EPS) of $0.85, reflecting a 10.5% decline from the previous year [2][6] - Revenue for the quarter is projected to be approximately $5.07 billion, a decrease of 3.1% from $5.23 billion reported in the same quarter last year [3][6] Market Position and Valuation - Kohl's has a price-to-earnings (P/E) ratio of 8.73, indicating a relatively low valuation compared to its earnings [4][6] - The price-to-sales ratio is 0.11, suggesting that investors are paying 11 cents for every dollar of sales [4] - The enterprise value to sales ratio is 0.53, reflecting the company's total value in relation to its sales [4] Financial Health - The enterprise value to operating cash flow ratio is 6.81, indicating cash flow generation relative to enterprise value [5] - The company's earnings yield is 11.46%, offering a substantial return on its earnings [5] - Kohl's has a debt-to-equity ratio of 1.73, indicating significant reliance on debt financing [5][6] - The current ratio of 1.30 suggests a reasonable level of liquidity to cover short-term liabilities [5]

Why Nvidia stock is soaring despite broader market sell-off?# Why Nvidia stock is soaring despite broader market sell-off?Stock marketAuthorDevesh KumarMar 09, 2026, 16:42 PM- Investors eye GTC 2026 for major AI hardware announcements from Nvidia.- Morgan Stanley names Nvidia its top chip pick with $260 price target.- Nvidia gains as broader market slides and stagflation fears shake Wall Street.Nvidia stock (NASDAQ: NVDA) is up roughly 1.2% on Monday, an unusual sight on a day when the Dow is down over 800 ...

An oil tanker carrying imported crude oil sails in the Jiaozhou Bay waterway towards Qingdao Port in Qingdao City, Shandong Province, China, on May 14, 2025. Energy ministers from the Group of Seven nations will hold a virtual meeting Tuesday morning to discuss a possible release of oil reserves to address the supply disruption triggered by the Iran war, sources told CNBC. G7 finance ministers met Monday to discuss a release of reserves but did not make a decision. The G7 members are Canada, France, Germany ...

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, inclusive (the "Class Period"). Please visit our website at http://www.gme-law.com for more information ...

Question-and-Answer Session And I might as well start with a little bit of a joke since we were just joking about this. You have your first new CEO since the first Bush administration. I know it's been a week, so I'm not asking for strategy but what about Fred, Fred's role, Fred's leadership brought him to Henry Schein? And what gets you excited about his skill set to bring to the next evolution of the company? Ronald South Senior VP & CFO Yes. Thank you, Michael, and good morning, everybody. Yes, we were c ...

By Jonathan Stempel According to the complaint, JPMorgan let CVS Caremark mark up prices of 366 generic drugs by an average 211%, causing some employees to pay more than uninsured patients. One drug, the multiple sclerosis medication teriflunomide, was marked up more than 38,000% to $6,229.23 from $16.20 for a 30-unit prescription, the complaint said. In her 34-page decision, Rochon dismissed claims that JPMorgan breached fiduciary duties of loyalty and prudence, saying "decisions about joint ventures, corp ...